|
|
Myasthenia Gravis Research Highlights: AAN 2024
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subtype of each patient as well as each patient’s comorbidities. There are currently five drugs approved by the FDA, eculizumab, efgartigimod, ravulizumab, rozanolixizumab, and zilucoplan. Clinical trial data on these therapies, as... |
|
|
Myasthenia Gravis Research Highlights: AAN 2024
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology and family practice. Other members of the care team may also participate.
Program Overview
This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.
Treatment of myasthenia gravis is highly individualized and depends greatly on the myasthenia gravis subt... |
|
|
Internal Medicine Comprehensive Review and Update 2025 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 65th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine... |
|
|
Gastroenterology 2025 - LIVE STREAMING
The Comprehensive 2025 Gastroenterology Update
This highly rated Harvard Medical School CME program ensures participants are current with state-of-the-art GI strategies and clinical practices. It covers recent advances and their impact on clinical approaches and on patient outcomes. Updates, best practices, and new guidelines are presented by nationally recognized GI experts and master clinicians.
Practical, Results-Driven Education
Highlights of the 2025 program include:
• The new... |
|
|
Thyroid Eye Disease Mastery: Multidisciplinary Approaches to Diagnosis and Treatment
Thyroid eye disease (TED) is a multifactorial autoimmune disease with widely varied signs and symptoms. It is believed to result from the stimulation of several receptors located in the orbital fibroblasts and is usually associated with hyperthyroidism. However, 5% of patients with TED have hypothyroidism, and 5% have no sign of thyroid disease; thus, it is frequently misdiagnosed. Misdiagnosis can place patients at risk for disfigurement and permanent vision loss, because treatment is most ef... |
|
|
Thyroid Eye Disease: Unmasking and Taming What’s in Disguise
Thyroid eye disease (TED) is a complex autoimmune-mediated inflammatory disorder of the orbit that is associated with a spectrum of signs and symptoms and varying levels of severity. Early diagnosis and initiation of appropriate treatment are imperative for preventing progression to severe disease and potential vision loss. However, diagnosis can be challenging. Traditional treatments for TED, such as steroids, radiotherapy, and surgery, all relieve symptoms but do not alter the course of dise... |
|
|
Solving the TED Puzzle: Answering Your Questions on Diagnosis to Decision-Making
Thyroid eye disease (TED) is a complex, autoimmune-mediated, inflammatory disorder of the orbit that presents with a range of symptoms, including ocular pain, dysmotility, and changes in ocular structure and function. The disease severely impacts patients' quality of life, often resulting in persistent discomfort, altered appearance, and impaired vision even after the acute phase subsides. Traditional treatments such as steroids, radiotherapy, and surgery, do not alter the disease's ... |
|